Leiden, The Netherlands, October 17th, 2011 – ISA Pharmaceuticals, a leader in the development of novel immunotherapeutic products for oncology and infectious diseases, today announced that Professor Jan van de Winkel has joined its Supervisory Board.
“We are excited to have Jan van de Winkel strengthening our Supervisory Board. He complements an experienced and motivated team, the collective experience of which spans the biotechnological, pharmaceutical and financial areas. We expect ISA to benefit from his insights and expertise and look forward to interacting with Jan to further propel the company in the rapidly emerging field of immunotherapy.” says Gerard Platenburg, managing
Leiden, The Netherlands, October 5th , 2011 – ISA Pharmaceuticals BV, a leader in the development of immunotherapeutic products for oncology and infectious diseases, today announced that orphan drug designation has been granted to its lead compound for the treatment of vulvar intraepithelial neoplasia (VIN) by the Office of Orphan Products Development (OOPD) of the US Food and Drug Administration (FDA). Orphan drug designation is granted by the FDA to promote the development of products that may offer therapeutic benefits for diseases affecting less than 200,000 people in the USA. Orphan drug designations are based on several criteria that include
ISA Pharmaceuticals B.V., a private, clinical stage company and leader in the development of immunotherapeutic products for oncology and infectious diseases, and Transgene (Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced the signing of an exclusive license agreement. Transgene will use ISA’s proprietary IP in Transgene’s program for developing novel vaccines to combat infectious diseases caused by mycobateria tuberculosis, such as TB. Under the terms of the agreement, ISA will receive an upfront fee and could receive payments on the achievement by Transgene of research and clinical milestones, as well as royalties on